On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

180 Life Sciences Corp. Bringing Hope to Those Afflicted by Dupuytren’s Disease and Other Inflammatory Conditions

  • 180 Life Sciences is a clinical-stage biotechnology company developing anti-tumor necrosis factor (“TNF”) therapies to treat a variety of inflammatory conditions.
  • Phase 2b/3 clinical trials on fibrosis and inflammation-causing TNF irregularity are currently underway with first results expected in 2021
  • The company is to be acquired by a SPAC (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF

Pioneering biotech company, 180 Life Sciences Corp. is bringing hope to sufferers of Dupuytren’s Disease and other inflammatory conditions caused by an impaired immune system. Currently, the company has three major programs underway focused on therapies for separate areas of inflammation. These programs are headed by a team of renowned scientists who have already developed blockbuster drugs, discovered an entire drug class and made ground-breaking discoveries in their fields. The programs are exploring therapies expected to bring relief to those afflicted by a variety of TNF conditions, including ‘frozen shoulder,’ Dupuytren disease, postoperative cognitive dysfunction (“POCD”), and non-alcoholic fatty liver disease (“NAFLD”).

TNF is one of those good things, a surfeit of which, can turn out bad. A protein released by white blood cells to mobilize the body’s defenses, i.e. the immune system, TNF plays an essential role in fighting off diseases of many kinds. TNF triggers inflammation to create an environment conducive to healing infected or damaged tissue. Typically, this state of affairs continues just long enough to repair damage to the cells. Regular or acute inflammation lasts for a short time, going away within hours or days. But sometimes, TNF sets the inflammatory process in motion when there’s no threat, a situation that can persist for a lengthy period, leading to what is known as chronic inflammation. Chronic inflammation opens a Pandora box of ailments. Conditions linked to chronic inflammation include Alzheimer’s disease, asthma, cancer, diabetes, heart disease, and a number of others that 180 Life Sciences Corp. is currently conducting research on.

The Company’s Three Research Programs Are: 

The fibrosis and anti-TNF program, based at the Kennedy Institute, University of Oxford, U.K.

The program is addressing four critical areas of inflammation:

  • Dupuytren disease, a debilitating condition that causes the fingers to irreversibly curl toward the palm. Dupuytren disease affects some 15 million Americans over the age of 35, about 5 percent of the U.S. population, according to a 2014 CDC study (https://ibn.fm/1G2pt). Top line data from Phase 2b/3 trials are expected by Q4 2021.
  • Frozen shoulder is a musculoskeletal impairment that makes it difficult or impossible to move the shoulders (https://ibn.fm/UBzDz). Phase 2b trials are set to begin Q3 2021.
  • POCD affects patients, particularly older ones, after surgical operations. In one study, roughly 12 percent of patients over age 60 had postoperative cognitive dysfunction, three months after surgery (https://ibn.fm/fuIDp). Phase 2 trials in POCD are anticipated to commence in Q4 2021.
  • Nonalcoholic steatohepatitis (“NASH”) is a type of non-alcoholic fatty liver disease, aggravated by hepatitis (https://ibn.fm/hxhA5). Preclinical studies in liver fibrosis and NASH are set to begin in late 2020.

 Synthetic CBD Analogs (“SCAs”) – Preclinical – based at the Hebrew University of Jerusalem

The SCA program is based at the Hebrew University of Jerusalem, in Israel, with additional research and trials at the Kennedy Institute, at the University of Oxford.

180 Life Sciences is aiming to develop SCAs that are safe and non-psychoactive and formulated to improve efficacy, as an alternative to naturally occurring cannabidiol (“CBD”). The program is led by a team that includes Professor Raphael Mechoulam, the first to ‘discover’ tetrahydrocannabinol (“THC”). 180 Life Sciences is aiming to create a compound that is 99.5% pure CBD, which will drastically improve medical prescriptive precision. The program is also exploring a drug delivery platform—ProNanoLipospheres (“PNL”)—to improve bioavailability.

The α7nAChR program, based at Stanford University in the US.

The α7nAChR program is searching for an effective therapy to treat ulcerative colitis in ex-smokers. α7nAChR is a nicotine receptor and is a central factor in the body’s method of controlling inflammation.

180 Life Sciences Corp. is to be acquired by KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC), after which the combined entity will be listed on Nasdaq under the ticker symbol: ATNF.

For more information, visit the companies’ websites at www.180LifeSciences.com and www.KBLMerger.com.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
[email protected]

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered